These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 30193813)
1. The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses. Bolduc M; Baz M; Laliberté-Gagné MÈ; Carignan D; Garneau C; Russel A; Boivin G; Savard P; Leclerc D Nanomedicine; 2018 Nov; 14(8):2563-2574. PubMed ID: 30193813 [TBL] [Abstract][Full Text] [Related]
2. A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling. Thérien A; Bédard M; Carignan D; Rioux G; Gauthier-Landry L; Laliberté-Gagné MÈ; Bolduc M; Savard P; Leclerc D J Nanobiotechnology; 2017 Jul; 15(1):54. PubMed ID: 28720097 [TBL] [Abstract][Full Text] [Related]
3. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine. Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362 [TBL] [Abstract][Full Text] [Related]
4. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA). Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805 [TBL] [Abstract][Full Text] [Related]
5. Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses. Tao W; Hurst BL; Shakya AK; Uddin MJ; Ingrole RS; Hernandez-Sanabria M; Arya RP; Bimler L; Paust S; Tarbet EB; Gill HS Antiviral Res; 2017 May; 141():62-72. PubMed ID: 28161578 [TBL] [Abstract][Full Text] [Related]
6. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Mozdzanowska K; Zharikova D; Cudic M; Otvos L; Gerhard W Virol J; 2007 Oct; 4():118. PubMed ID: 17974006 [TBL] [Abstract][Full Text] [Related]
7. Influenza Antigens NP and M2 Confer Cross Protection to BALB/c Mice against Lethal Challenge with H1N1, Pandemic H1N1 or H5N1 Influenza A Viruses. Mytle N; Leyrer S; Inglefield JR; Harris AM; Hickey TE; Minang J; Lu H; Ma Z; Andersen H; Grubaugh ND; Guina T; Skiadopoulos MH; Lacy MJ Viruses; 2021 Aug; 13(9):. PubMed ID: 34578289 [TBL] [Abstract][Full Text] [Related]
8. A novel M2e based flu vaccine formulation for dogs. Leclerc D; Rivest M; Babin C; López-Macias C; Savard P PLoS One; 2013; 8(10):e77084. PubMed ID: 24098576 [TBL] [Abstract][Full Text] [Related]
9. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats. Wang W; Huang B; Wang X; Tan W; Ruan L Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620 [TBL] [Abstract][Full Text] [Related]
11. Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice. Wang W; Li R; Deng Y; Lu N; Chen H; Meng X; Wang W; Wang X; Yan K; Qi X; Zhang X; Xin W; Lu Z; Li X; Bian T; Gao Y; Tan W; Ruan L Clin Vaccine Immunol; 2015 Jun; 22(6):618-30. PubMed ID: 25834017 [TBL] [Abstract][Full Text] [Related]
12. M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection. Tao W; Gill HS Vaccine; 2015 May; 33(20):2307-15. PubMed ID: 25842219 [TBL] [Abstract][Full Text] [Related]
13. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Denis J; Acosta-Ramirez E; Zhao Y; Hamelin ME; Koukavica I; Baz M; Abed Y; Savard C; Pare C; Lopez Macias C; Boivin G; Leclerc D Vaccine; 2008 Jun; 26(27-28):3395-403. PubMed ID: 18511159 [TBL] [Abstract][Full Text] [Related]
14. Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus. Lee YN; Kim MC; Lee YT; Kim YJ; Lee J; Kim C; Ha SH; Kang SM Antiviral Res; 2015 Oct; 122():82-90. PubMed ID: 26248203 [TBL] [Abstract][Full Text] [Related]
15. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e. Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216 [TBL] [Abstract][Full Text] [Related]
16. Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP]. Savard C; Laliberté-Gagné MÈ; Babin C; Bolduc M; Guérin A; Drouin K; Forget MA; Majeau N; Lapointe R; Leclerc D Vaccine; 2012 Mar; 30(15):2535-42. PubMed ID: 22326774 [TBL] [Abstract][Full Text] [Related]
17. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice. Lei H; Peng X; Jiao H; Zhao D; Ouyang J Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406 [TBL] [Abstract][Full Text] [Related]
19. A combination influenza mRNA vaccine candidate provided broad protection against diverse influenza virus challenge. Tian Y; Deng Z; Chuai Z; Li C; Chang L; Sun F; Cao R; Yu H; Xiao R; Lu S; Xu Y; Yang P Virology; 2024 Aug; 596():110125. PubMed ID: 38805804 [TBL] [Abstract][Full Text] [Related]